Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor plus (HR+), HER2-metastatic breast cancer (MBC) not previously treated with a taxane.

被引：1

作者：

Schwartzberg, Lee S.

Bondarenko, Igor

Tolaney, Sara M.

Seidman, Andrew David

O'Shaughnessy, Joyce

Shparyk, Yaroslav V.

Chung, Chi-Feng

Lu, Yen-Shen

Chic, Nuria

Panasci, Lawrence C.

Chae, Yee Soo

Recalde, Sabela

Hotko, Yevhen

Gomez, Patricia

Shaw Wright, Gail Lynn

Anthony Dacosta, Noshir

Vatandoust, Sina

O'Connell, Joseph P.

Wei, Thomas

Rugo, Hope S.

机构：

[1] West Canc Ctr, Memphis, TN USA

[2] City Clin Hosp 4, Dnipro, Ukraine

[3] Dana Farber Canc Inst, Boston, MA USA

[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[5] US Oncol, Texas Oncol Baylor Sammons Canc Ctr, Dallas, TX USA

[6] Lviv State Oncol Reg Med & Diagnost Ctr, Lvov, Ukraine

[7] Koo Fdn Sun Yat Sen Canc Ctr, Taipei, Taiwan

[8] Natl Taiwan Univ Hosp, Taipei, Taiwan

[9] Hosp Clin Barcelona, Barcelona, Spain

[10] Jewish Gen Hosp, Montreal, PQ, Canada

[11] Kyungpook Natl Univ Hosp, Daegu, South Korea

[12] Inst Catala Oncol Hosp Duran & Reynals, Barcelona, Spain

[13] Uzhgorod Natl Univ, Uzhgorod, Ukraine

[14] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Barcelona, Spain

[15] Sarah Cannon Res Inst & Florida Canc Specialists, New Port Richey, FL USA

[16] North Shore Hematol Oncol Associates, Stony Brook, NY USA

[17] Flinders Univ S Australia, Flinders Med Ctr, Adelaide, SA, Australia

[18] Odonate Therapeut Inc, San Diego, CA USA

[19] Univ Calif San Francisco, San Francisco, CA 94143 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.1061

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1061

引用

页数：3

共 50 条

[21] Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study
Xie, Yizhao
Li, Yi
Ting, Luo
Sang, Die
Yuan, Peng
Li, Wei
Li, Huihui
Ge, Rui
Wang, Biyun
FRONTIERS IN ONCOLOGY, 2021, 11
[22] Efficacy of vinorelbine plus trastuzumab (VT) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab (T).
Freixinos, V.
Sanchez-Olle, G.
De Mattos-Arruda, L.
Di Cosimo, S.
Saura, C.
Gomez, P.
Perez-Garcia, J. M.
Cortes, J.
Baselga, J.
Bellet, M.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[23] Saci-IO HR plus : Randomized phase II trial of sacituzumab govitecan (SG) plus /- pembrolizumab in PD-L1+hormone receptor-positive (HR+) / HER2-metastatic breast cancer (MBC).
Garrido-Castro, Ana Christina
Keenan, Tanya Elizabeth
Li, Tianyu
Lange, Paulina
Callahan, Catherine
Guerriero, Jennifer
Tayob, Nabihah
Anderson, Leilani
Stover, Daniel G.
Gogineni, Keerthi
Carey, Lisa A.
Nanda, Rita
Winer, Eric P.
Mittendorf, Elizabeth A.
Tolaney, Sara M.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[24] Neratinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2+metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.
Saura, Cristina
Oliveira, Mafalda
Feng, Yin-Hsun
Dai, Ming-Shen
Hurvitz, Sara A.
Kim, Sung-Bae
Moy, Beverly
Delaloge, Suzette
Gradishar, William John
Masuda, Norikazu
Palacova, Marketa
Trudeau, Maureen E.
Mattson, Johanna
Yap, Yoon Sim
Bryce, Richard
Yao, Bin
Bebchuk, Judith D.
Keyvanjah, Kiana
Brufsky, Adam
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[25] Metastatic patterns and outcomes by HER2 and hormone receptor (HR) status in patients (pts) with metastatic breast cancer (mBC)
Yuan, Qianyu
Castellanos, Emily
Fidyk, Erin
Schwed, Karen
Estevez, Melissa
Nemeth, Sheila
Linzmayer, Robin
Cohen, Aaron B.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[26] Biomarker analysis from a phase I study using gedatolisib plus palbociclib plus hormone therapy in ER+/HER2-metastatic breast cancer (mBC).
Wesolowski, Robert
Pathan, Nuzhat
Zhu, Zhou
Stringer-Reasor, Erica Michelle
Han, Hyo S.
Dees, Elizabeth Claire
Bardia, Aditya
Layman, Rachel M.
Weise, Amy
Kabos, Peter
Lu, Janice M.
Kern, Kenneth Alan
Pierce, Kristen J.
Rugo, Hope S.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[27] Real-world clinical outcomes in patients (pts) with HR+/HER2-metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US)
Tolaney, Sara M.
Punie, Kevin
Kurian, Allison W.
Ntalla, Ioanna
Verret, Wendy
Sadetsky, Natalia
Sjekloca, Nikoleta
Stokes, Michael
Jhaveri, Komal L.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[28] Real-world study of patients with HR+/ HER2-metastatic breast cancer treated with palbociclib and fulvestrant
Robert, Nicholas
Chen, Connie
Doan, Justin
Venkatasetty, Divea
Espirito, Janet L.
Aguilar, Kathleen M.
FUTURE ONCOLOGY, 2025, 21 (01) : 83 - 94
[29] Neratinib plus fulvestrant plus trastzuzumab (N plus F plus T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial.
Jhaveri, Komal L.
Goldman, Jonathan W.
Hurvitz, Sara A.
Guerrero-Zotano, Angel
Unni, Nisha
Brufsky, Adam
Park, Haeseong
Waisman, James Ross
Yang, Eddy Shih-Hsin
Spanggaard, Iben
Reid, Sonya A.
Burkard, Mark E.
Prat, Aleix
Loi, Sherene
Crown, John
Hanker, Ariella
Ma, Cynthia X.
Bose, Ron
Eli, Lisa DeFazio
Wildiers, Hans
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[30] Unmet need in heavily pre-treated patients with HR+/HER2-metastatic breast cancer (mBC) in the US: A ConcertAI analysis
Waks, A. G.
Gharaibeh, M.
Sjekloca, N.
Poluparthi, N.
Shah, A.
Bergamaco, E.
MacCannell, T.
Leung, G.
Ntalla, I.
Oko-osi, H.
Tolaney, S. M.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S653 - S653

← 1 2 3 4 5 →